Table 1.
Changes in rheumatoid arthritis disease activity indexes and levels of serological markers after the introduction of baricitinib.
| Week | 0 | 4 | 24 | 52 |
|---|---|---|---|---|
| CDAI | 57.2 | 4.0 | 6.0 | 6.5 |
| SDAI | 68.8 | 5.1 | 6.0 | 6.5 |
| DAS28-CRP | 7.61 | 3.00 | 2.29 | 2.34 |
| CRP (mg/dL) | 11.6 | 1.1 | 0.0 | 0.0 |
| ESR (mm/h) | 104 | 54 | 20 | 14 |
| RF (IU/mL) | 65 | 57 | 40 | 9 |
| MMP-3 (ng/mL) | 715.3 | 253.7 | 68.7 | 18.1 |
| SAA (μg/mL) | 789.0 | 89.7 | 7.4 | 5.0 |
| ACPA (IU/mL) | 3472 | — | — | 329.1 |
| HAQ | 2.000 | 0.500 | 1.000 | 1.375 |
CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; DAS28-CRP: disease activity score 28 based on C-reactive protein (CRP) level; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; MMP-3: matrix metalloproteinase-3; SAA: serum amyloid A; ACPA: anti-citrullinated protein antibody; HAQ: Health Assessment Questionnaire.